Half of all COPD and asthma hospitalizations are considered preventable. That single fact carries enormous weight when you consider that these two conditions cost the United States more than $50 billion annually, the majority of which flows directly from acute episodes that the right signal, seen early enough, could have interrupted. A June 2026 landmark study from Intermountain Health and CareCentra did not just suggest that AI-enhanced monitoring could change that equation. It proved it.
What the Intermountain and CareCentra Study Actually Found
The findings from this collaboration are specific enough to stop any skeptic mid-sentence. Patients enrolled in AI-enhanced monitoring for COPD and asthma saw a 50% reduction in hospitalizations and 20% fewer emergency department visits. Overall costs dropped by 57%. These are not marginal improvements attributed to general care coordination. They are the measurable result of structured, continuous data collection feeding into clinical decision support that reaches the right provider before a patient deteriorates past the point of outpatient intervention. For health systems managing large populations of patients with obstructive lung disease, this is the kind of outcome data that changes procurement conversations.
Why COPD Is the Ideal Proving Ground for AI Monitoring
COPD exacerbations rarely arrive without warning. Respiratory rate trends shift. Oxygen saturation dips incrementally. Activity levels quietly decline days before a patient calls their physician or, more commonly, shows up in the ED. The problem has never been a lack of signals. It has been the inability to collect those signals continuously, structure them into something readable, and route the right alert to the right provider in real time. AI-driven remote patient monitoring addresses all three gaps simultaneously. COPD also carries a readmission penalty risk under CMS programs, which means every prevented hospitalization protects both the patient and the health system's financial standing. The Intermountain and CareCentra results did not happen by accident. They happened because the monitoring infrastructure was designed to intervene upstream.
The $50 Billion Problem That Structured Data Can Shrink
COPD and asthma together represent one of the most expensive chronic disease burdens in American healthcare. The $50 billion annual cost is not driven by medication or routine visits. It is driven by the hospitalizations, the ICU stays, and the readmissions that follow when early warning signs go unmonitored between appointments. Fragmented records compound the problem. When a pulmonologist cannot see what happened during a patient's last urgent care visit, or when a primary care provider is reviewing notes from three different systems to piece together a respiratory history, the clinical picture is incomplete. Structured AI monitoring closes that gap by turning continuous health data into a single, organized view that supports faster, more confident clinical decisions.
From Data Collection to Clinical Action
The distinction that matters most in AI-driven monitoring is not how much data is collected. It is what happens to that data after collection. Passive data sitting in a portal does not prevent a hospitalization. Structured, prioritized, and clinician-readable summaries routed into existing workflows do. Platforms built for provider adoption integrate monitoring updates directly into the clinical dashboard, flagging patients whose biometric trends warrant same-day outreach before an exacerbation becomes an admission. For care teams managing panels of high-risk respiratory patients, that prioritization is not a convenience. It is the operational difference between proactive care and reactive crisis management. The 20% reduction in ED visits seen in the Intermountain and CareCentra study reflects exactly that shift in clinical posture.
What This Means for Your Patient Population Today
The case for AI-enhanced COPD monitoring has moved beyond pilot studies and theoretical frameworks. The 2026 Intermountain and CareCentra findings represent real patients, real hospitalizations avoided, and real cost reductions at scale. For health systems with significant COPD and asthma populations, the question is no longer whether AI monitoring works. The question is how quickly the infrastructure can be put in place to extend those outcomes to your patients. For patients and caregivers navigating a diagnosis that feels unpredictable, continuous structured monitoring offers something equally important: the confidence that changes in your condition will not go unnoticed between appointments.
A 50% reduction in hospitalizations does not happen because providers care more. It happens because the right information reaches the right person at the right moment. That is the promise of structured AI monitoring, and the Intermountain Health and CareCentra study shows it is a promise that can be kept.
See how MediClarity gives clinicians and patients one organized view of the full health story. Visit mediclarity.ai to learn more or request a demo.